Hiroki Kuniyasu

Prof. Hiroki Kuniyasu

Nara Medical University
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2012 in British Journal of Cancer
Verified
Journal Article
Open access
TST Sasahira
T Sasahira
MKM Kurihara
M Kurihara
UBU K Bhawal
U K Bhawal
NUNobuhiro Ueda
Nobuhiro Ueda
TST Shimomoto
T Shimomoto
HKHiroki Kuniyasu
Hiroki Kuniyasu
Background: Methods: Results: Conclusion:

25 October 2006 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KHKaeko Hirai
Kaeko Hirai
TSTomonori Sasahira
Tomonori Sasahira
HOHitoshi Ohmori
Hitoshi Ohmori
KFKiyomu Fujii
Kiyomu Fujii
HKHiroki Kuniyasu
Hiroki Kuniyasu
Heme oxygenase (HO)‐1 is a key player reducing cytotoxicity and enhancing protumoral effects of nitric oxide (NO). We examined zinc protoporphyrin (ZnPP) IX, an HO‐1 inhibitor, to affect tumor growth of LL/2 mouse lung cancer cells. ZnPPIX reduced HO‐1 expression and HO activity in LL/2 cells, whereas cobalt PPIX (CoPPIX), an HO‐1 activator, increased both. LL/2 cells treated with sodium nitropurusside, an NO donor, showed growth inhibition dose‐dependently, which was enhanced by ZnPPIX cotreatment, but was reduced by CoPPIX. In mice tumors, ZnPPIX decreased HO‐1 expression. LL/2‐tumors were found in 88% (7/8) vehicle‐treated mice, whereas tumors were found in 38% (3/8) and 25% (2/8) mice treated with 5 and 20 μg/mouse ZnPPIX, respectively ( p = 0.0302). Tumor growth was inhibited dose‐dependently by ZnPPIX. Vascular endothealial growth factor concentration in tumors was reduced by ZnPPIX ( p = 0.0341). Microvessel density (MVD) in ZnPPIX‐treated tumors was lower than that in vehicle‐treated tumors ( p = 0.0362). Apoptotic cell count in ZnPPIX‐treated tumors was higher than that in vehicle‐treated tumors ( p = 0.0003). In contrast, CoPPIX treatment increased HO‐1 expression, enhanced tumorigenicity and MVD and reduced apoptosis. From these findings, inhibition of HO‐1 by ZnPPIX provides relevant antitumoral effects.

13 February 2003 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
HKHiroki Kuniyasu
Hiroki Kuniyasu
YCYoshitomo Chihara
Yoshitomo Chihara
HKHideaki Kondo
Hideaki Kondo

24 March 2005 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
TSTomonori Sasahira
Tomonori Sasahira
YAYoshihiko Akama
Yoshihiko Akama
KFKiyomu Fujii
Kiyomu Fujii
HKHiroki Kuniyasu
Hiroki Kuniyasu

1 March 2005 in The American Journal of Pathology
Verified
Journal Article
Closed access
HKHiroki Kuniyasu
Hiroki Kuniyasu
SYSeiji Yano
Seiji Yano
TSTakamitsu Sasaki
Takamitsu Sasaki
TSTomonori Sasahira
Tomonori Sasahira
SSSabro Sone
Sabro Sone
HOHitoshi Ohmori
Hitoshi Ohmori

1 March 2003 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
HKHiroki Kuniyasu
Hiroki Kuniyasu
YCYoshitomo Chihara
Yoshitomo Chihara
TTTadateru Takahashi
Tadateru Takahashi
The clinical relevance of the receptor for advanced glycation end products (RAGE) and amphoterin expression was examined in 119 non-diabetic patients with colorectal carcinoma. Expression of RAGE was examined by immunohistochemistry and that of amphoterin by in situ hybridization. RAGE expression was observed in 55% (64/119) of the cases. RAGE positivity in Dukes' B, C and D cases was 19, 81 and 100%, respectively (p<0.0001). Amphoterin was expressed in most cases regardless of tumor stage. Survival analysis of Dukes' B and C cases showed a significantly poorer prognosis for patients with co-expression of RAGE and amphoterin than for patients without co-expression. The results suggest that co-expression of RAGE and amphoterin is closely associated with invasion and metastasis of colorectal cancer.